AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home iLIVER Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: Review and bibliometric

Pamela Scarlett Espinoza Loyolaa,c,d,e( ), Diana Laura Muratalla Bautistaa, Karen Adela Hernández Bautistaa, Elizabeth Gil Whiteb, José Antonio González Morenoc, Daniel Angel Torres del Realc, Víctor Manuel Páez Zayasd, Carla Escorza-Molinae, Fernando Mondragón Rodríguezc, Omar Vásquez Gómezc, Luis Jorge Fernández Lópezc, Paul Santiago Mogrovejo Vázquezc, Isidoro Aczel Sánchez-Cedilloc, Víctor Jose Visag Castilloc
Social Service Internship, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
Social Service Internship, Universidad Anahuac, Mexico City 04510, Mexico
Department of Surgery Division of Transplantation Surgery, Hospital General de México, Mexico City 06720, Mexico
Departament of Gastroenterology, Division of Hepatology, Hospital General de México, Mexico City 06720, Mexico
Departmanet of Anesthesiology, Hospital General de México, Mexico City 06720, Mexico
Show Author Information

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and is one of the leading indications for liver transplantation, liver transplantation is the gold standard treatment for end stage liver disease. Diagnosis is based up on radiological characteristics and rarely biopsy results. However treatment must be individualized to each patient to improve recurrences and outcomes. In this article, we focus on the different selection criteria for liver transplantation. This study aimed to investigate the distribution laws and research frontiers of international literature, so as to present holistic bibliometric evaluation of the studies on 5-year survival and disease-free recurrence in 5 years, according to hepatocarcinoma criteria for liver transplantation. The paper aims to review and analyze 5-year survival and disease-free recurrence based on hepatocarcinoma criteria for liver transplantation. It systematically examines and summarizes distribution characteristics and research frontiers through bibliometric analysis. A bibliographic search was implemented in PubMed/Medline, Clinical Key, Science Direct and Index Medicus with MESH terms, from the year 1996–2022. Patients selected for transplantation using the Metroticket 2.0 (MT2) criteria had the highest overall survival along with patients selected for transplantation using the Milan Criteria had the best 5-year disease-free recurrence. The Metroticket 2.0 criteria (MT2) and Milan Criteria (MC) have shown the most favorable post-transplant outcomes for patients with hepatocellular carcinoma (HCC). However, MC demonstrated the best 5-year disease-free recurrence rate, underscoring the significance of taking into account tumor morphology and biology when determining the eligibility of HCC patients for liver transplantation. The distribution characteristics and research frontiers by bibliometrics concerning prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma the collaborations are sufficient to reach a consensus that the Milan criteria are the best criteria.

Keywords

RecurrenceHepatocellular carcinomaBibliometricsSurvivalLiver transplantationCriteria

References

[1]

Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019[LinkOut].
Crossref Google Scholar
[2]

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557–76. https://doi.org/10.1053/j.gastro.2007.04.061[PubMed].
Crossref Google Scholar
[3]

Burra P, Burroughs A, Graziadei I, et al. EASL clinical practice guidelines: liver transplantation. J Hepatol 2016;64(2):433–85. https://doi.org/10.1016/j.jhep.2018.10.006m.
Crossref Google Scholar
[4]

Lingiah VA, Niazi M, Olivo R, et al. Liver transplantation beyond Milan criteria. J Clin Transl Hepatol 2020;8(1):69–75. https://doi.org/10.14218/JCTH.2019.00050[PubMed].
Crossref Google Scholar
[5]

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127):1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2[LinkOut].
Crossref Google Scholar
[6]

Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7: 6. https://doi.org/10.1038/s41572-020-00240-3[LinkOut].
Crossref Google Scholar
[7]

Sugawara Y, Hibi T. Surgical treatment of hepatocellular carcinoma. Biosci Trends 2021;15(3):138–41. https://doi.org/10.5582/bst.2021.01094[PubMed].
Crossref Google Scholar
[8]

Visag-Castillo V. Mini-review. liver transplantation for hepatocellular carcinoma. Rev Médica Del Hosp Gen De México 2018;81(2):97–101. https://doi.org/10.1016/j.hgmx.2016.10.003[LinkOut].
Crossref Google Scholar
[9]

Cisneros-Garza L, González-Huezo M, Moctezuma-Velázquez C, et al. Ⅱ Consenso mexicano de Carcinoma hepatocelular. Parte I: epidemiología y diagnóstico. Revista de Gastroenterología de México 2022;87(2):216–34. https://doi.org/10.1016/j.rgmx.2021.10.002.
Crossref Google Scholar
[10]

Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocell Carcinoma 2014;1:115–25. https://doi.org/10.2147/JHC.S44381[PubMed].
Crossref Google Scholar
[11]

Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127(5):S87–96. https://doi.org/10.1053/j.gastro.2004.09.020[LinkOut].
Crossref Google Scholar
[12]

Bustamante-Villagomez SK, Vásquez-Alvarez S, Gonzalez-Mejia ME, et al. Association between metabolic syndrome, socioeconomic status and quality of life in mexicans. Rev Med Inst Mex Seguro Soc 2021;59(6):490–9[PubMed].
Google Scholar
[13]

McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8(3):521–33. https://doi.org/10.1016/j.cld.2004.04.004[PubMed].
Crossref Google Scholar
[14]

Kim H, Park YN. Hepatocellular adenomas: recent updates. J Pathol Transl Med 2021;55(3):171–80. https://doi.org/10.4132/jptm.2021.02.27[PubMed].
Crossref Google Scholar
[15]

Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer 2017;16(1):149. https://doi.org/10.1186/s12943-017-0712-x[PubMed].
Crossref Google Scholar
[16]

Torbenson MS. Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes. Hum Pathol 2021;112:86–101. https://doi.org/10.1016/j.humpath.2020.12.009. PMID: 33387587; PMCID: PMC9258523.
Crossref Google Scholar
[17]

Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. AASLD practice guidelines. Hepatology 2011;53:1020–35.
Crossref Google Scholar
[18]
González-Aguirre. Carcinoma hepatocelular: diagnóstico y tratamiento. Gaceta Mexicana de Oncología; 2013[cited 2023 Aug 22], https://www.elsevier.es/es-revista-gaceta-mexicana-oncologia-305-articulo-carcinoma-hepatocelular-diagnostico-tratamiento.
[19]

Kim T, Murakami T, Takahashi S, et al. Optimal phases of dynamic CT for detecting hepatocellular carcinoma: evaluation of unenhanced and triple-phase images. Abdom Imag 1999;24(5):473–80. https://doi.org/10.1007/s002619900543 [PubMed].
Crossref Google Scholar
[20]

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76(3):681–93. https://doi.org/10.1016/j.jhep.2021.11.018[PubMed].
Crossref Google Scholar
[21]

Benson AB, D'Angelica MI, Abbott D, et al. NCCN guidelines insights: hepatobiliary cancers. J Natl Compr Cancer Network 2017;15(5):563–73. https://doi.org/10.6004/jnccn.2017.0059.
Crossref Google Scholar
[22]

Reig M, Forner A, Ávila MA, et al. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. e1–463.e30 Med Clínica Engl Ed 2021;156(9):463. https://doi.org/10.1016/j.medcle.2020.09.004[LinkOut].
Crossref Google Scholar
[23]

Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40(3):225–35. https://doi.org/10.1007/s00535-005-1566-3[LinkOut].
Crossref Google Scholar
[24]

Aravinthan AD, Bruni SG, Doyle AC, et al. Liver transplantation is a preferable alternative to palliative therapy for selected patients with advanced hepatocellular carcinoma. Ann Surg Oncol 2017;24(7):1843–51. https://doi.org/10.1245/s10434- 017-5789-3[PubMed].
Crossref Google Scholar
[25]

Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. Nat Commun 1996;334(11):693–9. https://doi.org/10.1056/nejm199603143341104[PubMed].
Crossref Google Scholar
[26]

Ruch B, Wagler J, Kumm K, et al. Hepatocellular carcinoma, alpha fetoprotein, and liver allocation for transplantation: past, present and future. Curr Oncol 2022; 29(10):7537–51. https://doi.org/10.3390/curroncol29100593[PubMed].
Crossref Google Scholar
[27]

Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33(6):1394–403. https://doi.org/10.1053/jhep.2001.24563 [PubMed].
Crossref Google Scholar
[28]

Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology 2016;64(6):2077–88. https://doi.org/10.1002/hep.28643[PubMed].
Crossref Google Scholar
[29]

Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018;154(1):128–39. https://doi.org/10.1053/j.gastro.2017.09.025[PubMed].
Crossref Google Scholar
[30]

Toniutto P, Fumolo E, Fornasiere E, et al. Liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a comprehensive review. J Clin Med 2021;10(17):3932. https://doi.org/10.3390/jcm10173932[PubMed].
Crossref Google Scholar
[31]

Rauchfuß F, Dondorf F, Fahrner R, et al. Searching the ideal hepatocellular carcinoma patient for liver transplantation: are the Toronto criteria a step in the right direction? Hepatobiliary Surg Nutr 2017;6(5):342–3. https://doi.org/10.21037/hbsn.2017.05.14[PubMed].
Crossref Google Scholar
[32]

Alim A, Erdogan Y, Dayangac M, et al. Living donor liver transplantation: the optimal curative treatment for hepatocellular carcinoma even beyond Milan criteria. Cancer Control 2021;28:10732748211011960. https://doi.org/10.1177/10732748211011960[PubMed].
Crossref Google Scholar
[33]

Chung H, Chapman WC. Liver transplantation for hepatocellular carcinoma: how far have we come and what is the future? Hepat Oncol 2014;1(3):309–21. https://doi.org/10.2217/hep.14.8[PubMed].
Crossref Google Scholar
[34]

Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10(1):35–43. https://doi.org/10.1016/s1470-2045(08)70284-5[PubMed].
Crossref Google Scholar
[35]

Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol 2017;14(4):203–17. https://doi.org/10.1038/nrgastro.2016.193[PubMed].
Crossref Google Scholar
[36]

Lozanovski VJ, Ramouz A, Aminizadeh E, et al. Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis. BJS Open 2022;6(1):zrab130. https://doi.org/10.1093/bjsopen/zrab130 [PubMed].
Crossref Google Scholar
[37]

Barreto SG, Strasser SI, McCaughan GW, et al. Expansion of liver transplantation criteria for hepatocellular carcinoma from Milan to UCSF in Australia and New Zealand and justification for metroticket 2.0. Cancers 2022;14(11):2777. https://doi.org/10.3390/cancers14112777[PubMed].
Crossref Google Scholar
[38]

Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13(1):e11–22. https://doi.org/10.1016/s1470-2045(11)70175-9[LinkOut].
Crossref Google Scholar
[39]

Limkemann AJP, Abreu P, Sapisochin G. How far can we go with hepatocellular carcinoma in living donor liver transplantation? Curr Opin Organ Transplant 2019;24(5):644–50. https://doi.org/10.1097/MOT.0000000000000692[PubMed].
Crossref Google Scholar
[40]

Unek T, Karademir S, Arslan NC, et al. Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol 2011; 17(37):4206–12. https://doi.org/10.3748/wjg.v17.i37.4206[PubMed].
Crossref Google Scholar
[41]

Bento de Sousa JH, Calil IL, Tustumi F, et al. Comparison between Milan and UCSF criteria for liver transplantation in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Gastroenterol Hepatol 2021;6:11. https://doi.org/10.21037/tgh.2020.01.06[PubMed].
Crossref Google Scholar
[42]

Mehta N. Liver transplantation criteria for hepatocellular carcinoma, including posttransplant management. Clin Liver Dis 2021;17(5):332–6. https://doi.org/10.1002/cld.1054[PubMed].
Crossref Google Scholar
[43]
Sc Lyu, Wang J, Ren Zy, et al. Prognosis of liver transplantation for hepatocellular carcinoma in terms of different criteria: a single center experience. CURR MED SCI 2022;42: 548–54. https://doi-org.pbidi.unam.mx:2443/10.1007/s11596-022-2558-8.
Crossref
[44]

DuBay D, Sandroussi C, Sandhu L, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011;253(1):166–72. https://doi.org/10.1097/sla.0b013e31820508f1[PubMed].
Crossref Google Scholar
[45]

Hanouneh IA, Macaron C, Lopez R, et al. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc 2011;43(10):3813–8. https://doi.org/10.1016/j.transproceed.2011.09.043[PubMed].
Crossref Google Scholar
[46]

Costentin CE, Bababekov YJ, Zhu AX, et al. Is it time to reconsider the Milan criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation? Hepatology 2019;69(3):1324–36. https://doi.org/10.1002/hep.30278[PubMed].
Crossref Google Scholar
[47]
Teng F, Han QC, Ding GS, et al. Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. Sci Rep 2015;5: 11733. https://doi-org.pbidi.unam.mx:2443/10.1038/srep11733.
Crossref
[48]

Toso C, Meeberg G, Hernandez-Alejandro R, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology 2015;62(1):158–65. https://doi.org/10.1002/hep.27787[PubMed].
Crossref Google Scholar
[49]

Grat M, Kornasiewicz O, Hołowko W, et al. Evaluation of total tumor volume and pretransplantation α-fetoprotein level as selection criteria for liver transplantation in patients with hepatocellular cancer. Transplant Proc 2013;45(5):1899–903. https://doi.org/10.1016/j.transproceed.2012.12.010 [PubMed].
Crossref Google Scholar
[50]

Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large euro-american series. Ann Surg Oncol 2015;22(7):2286–94. https://doi.org/10.1245/s10434-014-4273-6[PubMed].
Crossref Google Scholar
[51]

Chaiteerakij R, Zhang X, Addissie BD, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015;21(5):599–606. https://doi.org/10.1002/lt.24117[PubMed].
Crossref Google Scholar
[52]

Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7(11):2587–96. https://doi.org/10.1111/j.1600- 6143.2007.01965.x[PubMed].
Crossref Google Scholar
[53]

de Ataide EC, Garcia M, Mattosinho TJ, et al. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma. Transplant Proc 2012;44(8):2438–40. https://doi.org/10.1016/j.transproceed.2012.07.006[PubMed].
Crossref Google Scholar
[54]

Bonadio I, Colle I, Geerts A, et al. Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience. Clin Transplant 2015;29(5):425–33. https://doi.org/10.1111/ctr.12534[PubMed].
Crossref Google Scholar
[55]

Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022;28(23):2561–8. https://doi.org/10.3748/wjg.v28.i23.2561[PubMed].
Crossref Google Scholar
iLIVER
Volume 3 Issue 1,
March 2024
DOI: 10.1016/j.iliver.2024.100077
Cite this article:
Espinoza Loyola PS, Muratalla Bautista DL, Hernández Bautista KA, et al. Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: Review and bibliometric. iLIVER, 2024, 3(1). https://doi.org/10.1016/j.iliver.2024.100077

202

Views

0

Crossref

Altmetrics
Received: 23 September 2023
Revised: 29 November 2023
Accepted: 03 December 2023
Published: 06 February 2023
© 2024 The Author(s). Tsinghua University Press.

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Return